Veeva Systems Inc Class A VEEV

Morningstar Rating
$207.52 −0.10 (0.05%)
View Full Chart

Company Report

Veeva Earnings: Broad-Based Customer Wins and Margin Gains Mark a Strong Quarter; Shares Look Cheap

Wide-moat Veeva reported solid second-quarter results that came in above our expectations. Total sales of $676 million were up 14.6% year over year and beat our forecast of $670 million. The firm demonstrated strong performance throughout the customer size spectrum with wins from both large pharmas and small biotechs. Veeva also executed well on the cost-control front and margins for both subscription and services were lifted during the quarter. We think a favorable product mix, a headcount reduction, and an increased efficiency all drove the improvement. On the backdrop of a successful quarter, the firm inched up the low end of the sales guidance range about 1% and raised EPS guidance to $6.22 from $6.16. After updating our model and accounting for time value of money, we raise our fair value estimate to $273 per share from $270.

Price vs Fair Value

VEEV is trading at a 584% premium.
Price
$207.52
Fair Value
$842.00
Uncertainty
High
1-Star Price
$321.23
5-Star Price
$145.30
Economic Moat
Mcs
Capital Allocation
Mdbsphtyn

Bulls Say, Bears Say

Bulls

Veeva Vault continues to implement new products to its suite, which makes the offering even more attractive.

Bears

Moving its CRM from Salesforce’s platform to its Vault Platform could raise concerns for customers and lower its retention rate.

News

Trading Information

Previous Close Price
$207.62
Day Range
$205.78207.93
52-Week Range
$162.72236.90
Bid/Ask
$207.52 / $208.15
Market Cap
$33.60 Bil
Volume/Avg
704,341 / 889,520

Key Statistics

Price/Earnings (Normalized)
35.51
Price/Sales
13.24
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Sector
Healthcare
Industry
Health Information Services
Stock Style Box
Mid Growth
Total Number of Employees
7,172

Competitors

Valuation

Metric
VEEV
ORCL
CRM
Price/Earnings (Normalized)
35.5129.0729.64
Price/Book Value
6.4842.974.65
Price/Sales
13.248.827.51
Price/Cash Flow
36.4123.6019.17
Price/Earnings
VEEV
ORCL
CRM

Financial Strength

Metric
VEEV
ORCL
CRM
Quick Ratio
4.940.590.86
Current Ratio
5.010.721.04
Interest Coverage
4.474.66
Quick Ratio
VEEV
ORCL
CRM

Profitability

Metric
VEEV
ORCL
CRM
Return on Assets (Normalized)
16.61%11.77%9.78%
Return on Equity (Normalized)
20.63%259.97%15.73%
Return on Invested Capital (Normalized)
20.38%20.14%15.15%
Return on Assets
VEEV
ORCL
CRM

Health Information Services Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
GE HealthCare Technologies Inc Common Stock
GEHC
NfsykybpsXbs$41.6 Bil
Pro Medicus Ltd
PMCUF
Qfpvr$12.9 Bil
Solventum Corp
SOLV
Dcrnnhx$11.7 Bil
Doximity Inc Class A
DOCS
Wwxntp$8.1 Bil
Tempus AI Inc Class A common stock
TEM
Rylz$7.9 Bil
HealthEquity Inc
HQY
Cwcdn$6.9 Bil
M3 Inc
MTHRF
Qbblhg$6.9 Bil
M3 Inc ADR
MTHRY
Wspffm$6.9 Bil
R1 RCM Inc
RCM
Jnf$6.0 Bil

Sponsor Center